Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
RFG Advisory LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 13.4% in the fourth quarter, ...
"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...
Private Capital Advisors Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.1% during ...
The drug is chasing a market where Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) SGLT2 inhibitor looks likely to be the new pacesetter. It became the first ever diabetes drug to ...
Big Pharma is again raising the prices for key medications that could save the lives of millions in Georgia and there are ...
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
With the passage of the Inflation Reduction Act (IRA) we saw millions of insulin dependent Medicare beneficiaries receive ...
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...